Replies to post #128948 on Biotech Values

[dav1234]

i guess, VRUS near lows -$8+

[DewDiligence]

[Feuerstein is] just covering his ass over today’s column on VRUS.

I just read Feuerstein’s piece saying that VRUS might owe royalties to IDIX on its nuke IP, and I think there’s no substance to it. But this has nothing to do with the looming competition from ABT in all-oral HCV cocktails, which is presumably the reason for VRUS’ selloff today.